Transthyretin-directed RNA Interaction class drugs
3 results
Amvuttra (vutrisiran)
(VUTRISIRAN)Alnylam Pharmaceuticals, Inc.
Usage: AMVUTTRA is indicated for treating the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) and the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, focusing on reducing cardiovascular mortality, hospitalizations, and urgent heart failure visits.
Onpattro (patisiran)
(patisiran)Alnylam Pharmaceuticals, Inc.
Usage: ONPATTRO is indicated for treating polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults.
Wainua (eplontersen)
(EPLONTERSEN)AstraZeneca Pharmaceuticals LP
Usage: WAINUA is indicated for the treatment of polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults.